Narrow search
Showing 1 - 3 of 3
Cover Image
Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery
Holmes, Michael; Carroll, Christopher; Papaioannou, Diana - In: PharmacoEconomics 30 (2012) 2, pp. 137-146
The National Institute for Health and Clinical Excellence (NICE) invited Boehringer Ingelheim GmbH, the manufacturer of dabigatran etexilate (DBG), to submit evidence on the clinical and cost effectiveness of this drug for the primary prevention of venous thromboembolism (VTE) in adult patients...
Persistent link: https://www.econbiz.de/10011001782
Cover Image
Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery: A NICE Single Technology Appraisal
Holmes, Michael; Carroll, Christopher; Papaioannou, Diana - In: PharmacoEconomics 30 (2012) 2, pp. 137-146
The National Institute for Health and Clinical Excellence (NICE) invited Boehringer Ingelheim GmbH, the manufacturer of dabigatran etexilate (DBG), to submit evidence on the clinical and cost effectiveness of this drug for the primary prevention of venous thromboembolism (VTE) in adult patients...
Persistent link: https://www.econbiz.de/10010614405
Cover Image
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
Latimer, Nicholas; Carroll, Christopher; Wong, Ruth; … - In: PharmacoEconomics 32 (2014) 12, pp. 1171-1183
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment...
Persistent link: https://www.econbiz.de/10011152263